Clinomics Inc
Celestra Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company's liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (… Read more
Clinomics Inc (352770) - Total Assets
Latest total assets as of December 2024: ₩53.56 Billion KRW
Based on the latest financial reports, Clinomics Inc (352770) holds total assets worth ₩53.56 Billion KRW as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Clinomics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Clinomics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Clinomics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Clinomics Inc's total assets of ₩53.56 Billion consist of 12.3% current assets and 87.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 3.0% |
| Accounts Receivable | ₩378.06 Million | 0.7% |
| Inventory | ₩224.58K | 0.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩223.16 Million | 0.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Clinomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clinomics Inc's current assets represent 12.3% of total assets in 2024, a decrease from 55.1% in 2017.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2024, down from 25.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Clinomics Inc Competitors by Total Assets
Key competitors of Clinomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Clinomics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Clinomics Inc generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Clinomics Inc is currently not profitable relative to its asset base.
Clinomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.15 | 0.75 | 7.27 |
| Quick Ratio | 0.15 | 0.65 | 6.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-37.82 Billion | ₩ -6.08 Billion | ₩ 10.26 Billion |
Clinomics Inc - Advanced Valuation Insights
This section examines the relationship between Clinomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.47 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -28.1% |
| Total Assets | ₩53.56 Billion |
| Market Capitalization | $416.24K USD |
Valuation Analysis
Below Book Valuation: The market values Clinomics Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Clinomics Inc's assets decreased by 28.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Clinomics Inc (2017–2024)
The table below shows the annual total assets of Clinomics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩53.56 Billion | -28.09% |
| 2023-12-31 | ₩74.48 Billion | -23.29% |
| 2022-12-31 | ₩97.10 Billion | -5.35% |
| 2021-12-31 | ₩102.59 Billion | +134.43% |
| 2020-12-31 | ₩43.76 Billion | +62.46% |
| 2019-12-31 | ₩26.94 Billion | +266.61% |
| 2018-12-31 | ₩7.35 Billion | +193.02% |
| 2017-12-31 | ₩2.51 Billion | -- |